LGVN - Is Longeveron a Good Biotech Stock to Buy?
How much would you pay for a chance to stay healthy and vibrant for a few extra decades?
An American biotechnology company located in Miami of all places has convinced more than a few investors that its cellular therapy candidate can reverse common effects of aging. This November, shares of Longeveron (NASDAQ: LGVN) shot up more than 10-fold. Unfortunately, the gains didn't last long.
Longeveron stock has tumbled to around 44% below the peak it reached in November. Investors who missed the boat the first time around are wondering if Longeveron the recent slide is an opportunity to buy a potential long-term winner at a relative discount.
For further details see:
Is Longeveron a Good Biotech Stock to Buy?